Skip to main content

Table 3 Complications

From: Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial

Variable

Group A (n = 60)

Group B (n = 60)

Group (n = 60)

P Value

Complications

 DVT

0

0

0

NA

 IMVT

3

3

2

0.877

 Nausea

3

2

4

0.704

 Pyrexia

3

2

2

0.862

 Headache

1

2

1

0.774

 Muscle pain

2

1

1

0.774

  1. NA not applicable, DVT deep vein thrombosis, IMVT intermuscular vein thrombosis
  2. The p value represents the result of the chi-squared test or Fisher's exact tests for categorical variables among the 3 groups
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us